New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01)

The summary for the New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01): The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for projects to identify targets whose inhibition would induce synthetic lethality in cancers dependent on the expression of mutant KRas alleles. Despite recent advances in understanding the structural and biological complexities of mutant Ras proteins, the development of appropriate and effective methods to inhibit mutant Ras-dependent cancers has been hindered by the inability to directly target mutant Ras and the complexity of Ras processing, effector, and regulatory networks. Through this FOA, the NCI seeks to stimulate research that uses advanced or improved approaches for synthetic lethality screens that have greater specificity, reproducibility, and activity in physiologically relevant model systems than those used previously in first generation screening approaches. This FOA serves to engage extramural investigators in the mission of the NCI Frederick National Laboratory for Cancer Research (FNLCR) RAS Program to find ways to target Ras-dependent cancers. Investigators supported by this FOA will form a network to interact closely with the FNLCR RAS Program, actively exchange results across the network, and participate in cross-validation of potential targets identified by other awardees.
Federal Grant Title: New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-14-314
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.396
CFDA Descriptions: Cancer Biology Research
Current Application Deadline: Jul 8, 2015
Original Application Deadline: Jul 8, 2015
Posted Date: Aug 7, 2014
Creation Date: Aug 7, 2014
Archive Date: Aug 8, 2015
Total Program Funding:
Maximum Federal Grant Award: $750,000
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
For profit organizations other than small businesses
County governments
City or township governments
Special district governments
Independent school districts
Native American tribal organizations (other than Federally recognized tribal governments)
State governments
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
Additional Information on Eligibility
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PAR-14-314.html
Grant Announcement Contact
NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Opt...
Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allow...
Advancing Cancer Control Equity Research Through Transformative Solutions (U19 Clinical Tr...
Advancing Cancer Control Equity Research through Transformative Solutions Coordination Cen...
Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial O...
Mouse Models of Human Cancers Consortium
Integrative Cancer Biology Programs
Memory T Lymphocytes in Cancer Immunology (R21)
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com